1-3 of 3
Jonas S Heitmann, MD
Close
Sort by
Journal Articles

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Jonas S. Heitmann, MD, Daniela Dörfel, MD, Sabine Kayser, MD, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, MD, Wolfgang Bethge, MD, Ludger Grosse-Hovest, Martin Steiner, Melanie Märklin, PhD, Juliane S. Walz, MD, Richard F. Schlenk, Gundram Jung, MD, Helmut R. Salih
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-139493
Published: 2020
Journal Articles

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Sabine Kayser, MD, Jonas S. Heitmann, MD, Daniela Dörfel, MD, Felicitas Thol, MD, Michael Heuser, MD, Melanie Märklin, PhD, Carsten Müller-Tidow, MD, Martin Steiner, Ludger Grosse-Hovest, Gundram Jung, MD, Richard F. Schlenk, MD, Helmut R. Salih, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3928.
https://doi.org/10.1182/blood-2019-125327
Published: 2019
Journal Articles

Knock-Down of the NFAT2 Long and Intermediate Isoforms Leads to CLL Acceleration

Jonas S Heitmann, MD, Melanie Märklin, PhD, Posdorowkin Anastasia, B.Sc, Alexander R Fuchs, M.Sc., Felicia M Truckenmüller, Hans-Georg Kopp, MD, Lothar Kanz, MD, Anjana Rao, PhD, Stefan Wirths, MD, Martin R Mueller, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4371.
https://doi.org/10.1182/blood.V128.22.4371.4371
Published: 2016